Side-by-side · Research reference

GonadorelinvsLivagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED7/61 cited

BAnimal-StrongHUMAN-REVIEWED20/32 cited

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

01Mechanism of Action

Parameter

Gonadorelin

Livagen

Primary target

GnRH receptors on anterior pituitary gonadotropes

Hepatocyte protein synthesis machineryBrodskiĭ 2001

Pathway

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Downstream effect

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Feedback intact?

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

—

Origin

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Antibody development

—

02Dosage Protocols

Parameter

Gonadorelin

Livagen

Diagnostic test (pituitary function)

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

—

Therapeutic (hypothalamic hypogonadism)

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

—

Pulsatile interval

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

—

Route

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

Duration

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

—

Evidence basis

RCT / Expert consensus

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Half-life

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

—

Alternative protocols

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

—

Animal dose (oral)

—

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

Duration (experimental)

—

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

Human data

—

None in provided literature

03Metabolic / Fat Loss Evidence

Parameter

Gonadorelin

Livagen

Fat loss mechanism

None — gonadorelin acts exclusively on reproductive axis

—

Indirect metabolic effects

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

—

04Side Effects & Safety

Parameter

Gonadorelin

Livagen

Injection site reaction

Erythema, irritation (pulsatile pump catheter site)

—

Headache

Common with bolus administration

—

Nausea / abdominal discomfort

Transient, dose-related

—

Ovarian hyperstimulation syndrome (OHSS)

Risk with ovulation induction protocols; monitor follicular development via ultrasound

—

Multiple gestation

Increased risk with fertility protocols (twins ~10–15%)

—

Anaphylaxis

Rare hypersensitivity reaction

—

Pump malfunction / infection

Mechanical failure or catheter-site infection with long-term IV pump use

—

Receptor desensitization

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

—

Reported adverse effects

—

None documented in animal studies

Human safety data

—

No human trials in provided literature

Peptide hydrolysis

—

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

Absolute Contraindications

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Livagen

—

Relative Contraindications

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

Livagen

—

05Administration Protocol

Parameter

Gonadorelin

Livagen

1. Diagnostic protocol

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

2. Therapeutic pump setup (pulsatile)

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

3. Reconstitution

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

4. Monitoring

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

—

5. Timing

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

—

06Stack Synergy

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function

Livagen

— no documented stacks